Following public health emergencies such as the 2001 anthrax attacks and the 2009 H1N1 influenza pandemic, which raised concerns about the nation’s vulnerability to new infectious diseases and chemical, biological, radiological, and nuclear threats, the Department of Health and Human Services (DHHS) has become a key agency marshaling development and procurement of countermeasures such as drugs, vaccines, and diagnostic medical devices. But a December 27 report by the Government Accountability Office (GAO) found that the DHHS has not made public any spending estimates for its medical countermeasure development or procurement priorities, which may discourage potential developers from creating such countermeasures (http://1.usa.gov/1ar1oOY).
Mitka M. GAO: Spending Estimates for National Preparedness Needed From DHHS. JAMA. 2014;311(6):564. doi:10.1001/jama.2014.542